Enanta Pharmaceuticals (NASDAQ:ENTA) Rating Reiterated by JMP Securities

JMP Securities reissued their market outperform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a report published on Friday morning, Benzinga reports. JMP Securities currently has a $22.00 target price on the biotechnology company’s stock.

ENTA has been the topic of a number of other research reports. Evercore ISI raised shares of Enanta Pharmaceuticals to a strong-buy rating in a report on Tuesday, August 6th. JPMorgan Chase & Co. reduced their target price on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an underweight rating on the stock in a research report on Tuesday, August 6th. Finally, HC Wainwright reiterated a buy rating and set a $27.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of Hold and a consensus price target of $19.00.

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA opened at $10.36 on Friday. Enanta Pharmaceuticals has a 52-week low of $8.08 and a 52-week high of $17.80. The stock has a fifty day moving average of $12.70 and a 200 day moving average of $13.43. The firm has a market capitalization of $219.41 million, a price-to-earnings ratio of -1.66 and a beta of 0.59.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.43) by $0.36. The firm had revenue of $17.97 million during the quarter, compared to analyst estimates of $17.44 million. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. The company’s revenue was down 4.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.27) earnings per share. Equities analysts forecast that Enanta Pharmaceuticals will post -5.3 earnings per share for the current fiscal year.

Insider Transactions at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, insider Scott T. Rottinghaus sold 5,375 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $17.08, for a total transaction of $91,805.00. Following the completion of the sale, the insider now directly owns 21,717 shares of the company’s stock, valued at $370,926.36. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Enanta Pharmaceuticals news, insider Scott T. Rottinghaus sold 4,299 shares of the stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $15.07, for a total transaction of $64,785.93. Following the completion of the sale, the insider now directly owns 23,988 shares of the company’s stock, valued at approximately $361,499.16. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Scott T. Rottinghaus sold 5,375 shares of the stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $17.08, for a total transaction of $91,805.00. Following the transaction, the insider now directly owns 21,717 shares of the company’s stock, valued at approximately $370,926.36. The disclosure for this sale can be found here. Company insiders own 13.64% of the company’s stock.

Institutional Trading of Enanta Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC lifted its holdings in shares of Enanta Pharmaceuticals by 65.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock worth $588,000 after acquiring an additional 18,003 shares during the last quarter. American Century Companies Inc. raised its position in Enanta Pharmaceuticals by 35.4% in the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock worth $362,000 after purchasing an additional 7,287 shares during the period. Quest Partners LLC lifted its stake in Enanta Pharmaceuticals by 511.2% in the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 9,692 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Enanta Pharmaceuticals by 4.7% during the second quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company’s stock valued at $448,000 after buying an additional 1,548 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new position in shares of Enanta Pharmaceuticals during the second quarter valued at approximately $35,000. 94.99% of the stock is currently owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.